Kodiak Sciences Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Victor Perlroth
- Full Time Employees
- 130
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1200 Page Mill Road Palo Alto CA United States of America 94304
- IPO Date
- Oct 4, 2018
- CIK
- 0001468748
- Website
- kodiak.com
- Similar Companies
- Business
- Kodiak Sciences Inc. is a biopharmaceutical company engaged in the research, development, and commercialization of innovative treatments for prevalent retinal diseases. The company leverages its proprietary Antibody Biopolymer Conjugate (ABC®) platform to create long-acting therapies. Its lead investigational product, tarcocimab tedromer, an anti-vascular endothelial growth factor (VEGF) agent, has progressed through multiple Phase 3 clinical studies for various retinal vascular conditions, including diabetic retinopathy, retinal vein occlusion, and wet age-related macular degeneration. The tarcocimab program was recently re-evaluated and is advancing with ongoing Phase 3 trials, GLOW2 for diabetic retinopathy and DAYBREAK for wet age-related macular degeneration, with topline results anticipated in 2026. Kodiak's pipeline also features KSI-501, a bispecific antibody biopolymer conjugate designed to inhibit both VEGF and interleukin-6 (IL-6) for retinal conditions with an inflammatory component, currently in a Phase 3 study for wet age-related macular degeneration, with topline data expected in 2026. Additionally, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF, has shown promising Phase 1b results for macular edema secondary to inflammation, and is now in two Phase 3 studies, PEAK and PINNACLE, with data expected in late 2026 and early 2027. In preclinical development, KSI-601 is a triplet inhibitor being explored for dry age-related macular degeneration. The company was established in 2009, initially as Oligasis, LLC, adopting the name Kodiak Sciences Inc. in September 2015, and operates from Palo Alto, California.
Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus
Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results
KOD Begins Late-Stage Study of KSI-501 in Diabetic Macular Edema
Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema
Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026
Kodiak Sciences (NASDAQ:KOD) Shares Up 6.6% – What’s Next?
Kodiak Sciences: Clinical Redemption Is Turning Into Platform Leverage
Kodiak CFO Sells $1 Million in Stock as Shares Surge 650%. What Investors Should Know
Kodiak Stock Rises 35% in 3 Months: Here's What You Need to Know
Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference
Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally
Kodiak's Q1 Loss Wider Than Expected, Pipeline Development in Focus
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results
Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences
Kodiak Sciences (KOD) Up 2% Since Last Earnings Report: Can It Continue?
Kodiak Q4 Loss Wider Than Expected, Pipeline Development in Focus
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
Kodiak Sciences: Road To $120
Kodiak Sciences (NASDAQ:KOD) Reaches New 52-Week High – Time to Buy?
KOD Stock Soars on Promising Phase III Data for Eye Disease Candidate